Braveheart Bio CEO buys shares and receives options
Braveheart Bio, Inc. CEO and President Murdoch Travis reported two insider transactions.
Rhea-AI Filing Summary
Braveheart Bio, Inc. CEO and President Murdoch Travis reported two insider transactions. On August 7, 2026, he purchased 83,333 shares of common stock at $18.00 per share, bringing his direct common stock holdings to 2,940,670 shares. On August 5, 2026, he received a grant of 550,000 stock options with an exercise price of $19.80 per share, expiring August 4, 2031; 1/48 of the options vest monthly starting July 23, 2026. Additional common shares are held indirectly through family trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 83,333 shares
Net Buy
5 txns
Insider
Murdoch Travis
Role
CEO and President
Bought
83,333 shs ($1.50M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 83,333 | $18.00 | $1.50M |
| Grant/Award | Stock Option (Right to Buy) F2 | 550,000 | $0.00 | $0.00 |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 550,000 contracts (Direct);
Common Stock — 2,940,670 shares (Direct);
Common Stock — 3,338,175 shares (Indirect, By Murdoch Family Trust);
Common Stock — 1,027,396 shares (Indirect, By Irrevocable Gift Trust for Alizee);
Common Stock — 1,027,396 shares (Indirect, By Irrevocable Gift Trust for Siena)
Footnotes (2)
- F1. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
- F2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Common shares purchased: 83,333 shares at $18.00 per share
Direct common stock holdings: 2,940,670 shares
Stock options granted: 550,000 options at $19.80 exercise price
+4 more
7 metrics
Common shares purchased
83,333 shares at $18.00 per share
Open-market or private purchase on August 7, 2026
Direct common stock holdings
2,940,670 shares
Shares directly held by Murdoch Travis after August 7, 2026 purchase
Stock options granted
550,000 options at $19.80 exercise price
Grant on August 5, 2026, expiring August 4, 2031
Option vesting schedule
1/48 monthly from July 23, 2026
Vesting contingent on continuous service to issuer
Murdoch Family Trust holdings
3,338,175 shares
Indirect common stock holdings via Murdoch Family Trust
Alizee Gift Trust holdings
1,027,396 shares
Indirect holdings via Irrevocable Gift Trust for Alizee
Siena Gift Trust holdings
1,027,396 shares
Indirect holdings via Irrevocable Gift Trust for Siena
Key Terms
Stock Option (Right to Buy), exercise price, beneficial ownership, pecuniary interest, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "19.8000" per share exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
Irrevocable Gift Trust financial
"nature_of_ownership: "By Irrevocable Gift Trust for Alizee""
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Braveheart Bio (BRVE) CEO Murdoch Travis buy on August 7, 2026?
Murdoch Travis purchased 83,333 shares of Braveheart Bio common stock at a price of $18.00 per share on August 7, 2026, increasing his directly held common stock position.
What stock options were granted to the Braveheart Bio (BRVE) CEO on August 5, 2026?
On August 5, 2026, Murdoch Travis received a grant of 550,000 stock options with an exercise price of $19.80 per share, expiring on August 4, 2031, covering an equivalent number of common shares.
How do the Braveheart Bio (BRVE) CEO’s new options vest?
The 550,000 stock options vest as follows: 1/48 of the shares vest monthly on each monthly anniversary of July 23, 2026, subject to Murdoch Travis’s continuous service to Braveheart Bio on each vesting date.
What indirect Braveheart Bio (BRVE) holdings are associated with Murdoch Travis?
Indirect holdings include 3,338,175 shares via the Murdoch Family Trust and 1,027,396 shares each via Irrevocable Gift Trusts for Alizee and Siena. He disclaims beneficial ownership except for any pecuniary interest.
Were the Braveheart Bio (BRVE) CEO’s transactions under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirmative, so the reported purchase and option grant are not designated in this filing as executed under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
